Femasys (NASDAQ:FEMY – Get Rating) and Akili (NASDAQ:AKLI – Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, earnings, profitability, dividends, analyst recommendations and institutional ownership.
Profitability
This table compares Femasys and Akili's net margins, return on equity and return on assets.
Get Femasys alerts:| Net Margins | Return on Equity | Return on Assets | |
| Femasys | -886.22% | -48.96% | -44.68% |
| Akili | N/A | -53.80% | -5.15% |
Analyst Recommendations
This is a summary of current recommendations and price targets for Femasys and Akili, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Femasys | 0 | 0 | 3 | 0 | 3.00 |
| Akili | 0 | 1 | 4 | 0 | 2.80 |
Insider & Institutional Ownership
7.5% of Femasys shares are held by institutional investors. Comparatively, 78.0% of Akili shares are held by institutional investors. 20.8% of Femasys shares are held by company insiders. Comparatively, 20.4% of Akili shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Valuation and Earnings
This table compares Femasys and Akili's top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Femasys | $1.18 million | 9.31 | -$7.54 million | ($0.79) | -1.18 |
| Akili | N/A | N/A | -$2.44 million | N/A | N/A |
Akili has lower revenue, but higher earnings than Femasys.
Volatility & Risk
Femasys has a beta of -0.31, indicating that its stock price is 131% less volatile than the S&P 500. Comparatively, Akili has a beta of 0.79, indicating that its stock price is 21% less volatile than the S&P 500.
Summary
Akili beats Femasys on 6 of the 11 factors compared between the two stocks.
About Femasys
(Get Rating)
Femasys Inc., a biomedical company, focuses on women's healthcare market in the United States. The company develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; FemCerv, a biopsy device for endocervical curettage; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. It also commercializes FemVue saline-air device in the United States, Europe, Canada, Japan, and internationally. The company offers its infertility products to obstetrics-gynecological physicians, related healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. In addition, it provides non-surgical product technologies. Femasys Inc. was incorporated in 2004 and is based in Suwanee, Georgia.
About Akili
(Get Rating)
Akili, Inc., a digital medicine company, develops digital therapeutics for cognitive impairments. It provides EndeavorRx, a physician-prescribed video game-based treatment designed to directly target cognitive functioning. The company is based in Boston, Massachusetts.
Receive News & Ratings for Femasys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Femasys and related companies with MarketBeat.com's FREE daily email newsletter.